Lyell Immunopharma, Inc.
LYEL
$17.92
-$1.10-5.78%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 19.98% | -59.65% | -57.61% | -46.50% | -46.18% |
| Total Depreciation and Amortization | -41.22% | -27.94% | -18.94% | -10.86% | -3.06% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -25.18% | 423.85% | 381.34% | 241.94% | 247.15% |
| Change in Net Operating Assets | -217.12% | -635.47% | -21,665.12% | -309.94% | -191.20% |
| Cash from Operations | 7.62% | -5.92% | -8.24% | -9.79% | 0.79% |
| Capital Expenditure | -68.10% | -16.85% | 11.02% | 42.52% | 82.73% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -31.42% | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -37.90% | 644.50% | 154.49% | 15.34% | -17.40% |
| Cash from Investing | -55.81% | 537.40% | 108.44% | -2.30% | -33.48% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 3,495.36% | 2,640.71% | -67.64% | -43.60% | -36.27% |
| Repurchase of Common Stock | 98.68% | 100.00% | 100.00% | 100.00% | 83.37% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 3,701.36% | 2,971.66% | -58.74% | -29.31% | -23.92% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -17.80% | 113.22% | 63.36% | -124.15% | -274.88% |